Retinal
CAS 116-31-4
Retinal (CAS 116-31-4) is a pharmaceutical compound with 3 bioactivity targets and 5 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 38276.478688524585 nM | 61 | - |
| - | IC50 | 185 nM | 2 | - |
| - | EC50 | 200 nM | 1 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| CNGA2 Cnga2 |
Antagonist | 4.57 pIC50 | 12034887 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| RETINAL, ALL-TRANS | 2268087 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Retinal used for in pharmaceutical contexts?
Retinal (CAS 116-31-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Retinal?
Retinal has 5 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Alopecia, Burning sensation, Illness, Urinary tract infection, Weight decreased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Retinal also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for RETINAL with EU status "permitted".
What clinical phase is Retinal in?
No phase 1-4 clinical development badge is rendered for Retinal because the matched compound identifier rows do not contain a max-phase value.